Drug Profile
Research programme: lysis deficient phage therapy - GangaGen
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator GangaGen
- Class Antibacterials; Bacteriophages
- Mechanism of Action Bacterial DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Clostridium-difficile-infections in USA
- 15 Jul 2016 Early research in Clostridium difficile infections in USA (unspecified route)